[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629461":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":38,"collaborators":42,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":33,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":73,"whyStopped":33,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":33},{"fullName":5,"class":6},"Polytechnic Institute of Porto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"iTBS","EXPERIMENTAL","iTBS Group (n=44) will receive high-frequency (50 Hz) left-side DLPFC iTBS (120% RMT stimulation intensity; 50 Hz frequency; 2s on and 8 s off; 600 pulses\u002Fsession; total duration of 3 minutes). Treatment comprised 20 sessions in total, which consisted of once-daily sessions (on weekdays).",[13],"Device: Repetitive transcranial magnetic stimulation (rTMS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Repetitive transcranial magnetic stimulation (rTMS)","Each participant's resting motor threshold (RMT) will be determined by visual observation in accordance with standard clinical practice. Intermittent theta-burst stimulation (iTBS) will be delivered over the left dorsolateral prefrontal cortex (DLPFC) using these parameters: stimulation intensity 120% RMT; bursts at 50 Hz; 2 s on and 8 s off; 600 pulses per session; total stimulation time approximately 3 minutes per session. Stimulation will be delivered using a MagPro X100 stimulator with MagOption, equipped with a B70 butterfly-shaped coil with static cooling (MagVenture, Denmark). Treatment will comprise 20 sessions, delivered once daily on weekdays.",[9],[21,22,23,9],"Active rTMS","DLPFC rTMS","Active iTBS",[25],{"name":26,"affiliation":5,"role":27},"Catarina C Mateus, PhD","STUDY_DIRECTOR",[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Inês Duarte D Pais, MSc","CONTACT","+351 917750656",null,"idp@ess.ipp.pt",{"name":26,"role":31,"phone":36,"phoneExt":33,"email":37},"+351 962662157","cms@ess.ipp.pt",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Catarina Mateus, PhD","Associate Professor",[43],{"name":44,"class":45},"Hospital de Sao Joao, Porto","UNKNOWN","100629461","iprgc-as-a-potential-biomarker-for-predicting-transcranial-magnetic-stimulation-treatment-response-in-major-depressive-disorder-100629461",false,"NCT07474974","ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder","Illuminating Depression: ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder","BRIGHT","Inclusion Criteria:\n\n* Diagnosis of MDD, confirmed via the structured clinical interview;\n* TRD type;\n* Age between 18-65 years;\n* Visual acuity of 20\u002F32 or better.\n\nExclusion Criteria:\n\n* Prior rTMS treatment;\n* Contraindications for TMS;\n* Psychiatric disorders other than MDD;\n* Systemic diseases affecting the eyes (e.g., diabetes mellitus);\n* Ocular conditions;\n* Head injuries causing loss of consciousness;\n* Current or past alcohol\u002Fsubstance dependence within 6 months;\n* Neurodegenerative diseases;\n* Major neurological illnesses;\n* Use of medications affecting iris mechanics or the autonomic nervous system.","ALL","18 Years","65 Years",{"count":58,"type":59},44,"ESTIMATED","INTERVENTIONAL",[62],"NA","This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in treatment-resistant depression (TRD). We also aim to assess the impact of TMS treatment on RGCs and ipRGCs in TRD patients, investigating associations with clinical improvements and cognitive status. A clinical trial involving 44 patients with treatment-resistant depression (TRD) will be conducted. All participants will receive rTMS targeting the dorsolateral prefrontal cortex (DLPFC). Data will be collected pre- and post-intervention, as well as at a 2-month follow-up, using multiple outcome measures, including the post-illumination pupil response (PIPR). The project seeks to confirm the effectiveness of TMS and the potential of RGCs\u002FipRGCs as predictors of treatment response, thereby facilitating the development of personalized treatment strategies for TRD patients undergoing rTMS therapy.",[65,66],"Depression - Major Depressive Disorder","Treatment Resistant Depression",[68,69,70,71,72],"Major Depressive Disorder","Repetitive Transcranial Magnetic Stimulation","Retinal Ganglion Cells","ipRGCs","Treatment-resistant depression","NOT_YET_RECRUITING","2026-03-11",{"date":76,"type":77},"2026-03-16","ACTUAL",{"date":79,"type":59},"2026-03-15",{"date":81,"type":59},"2027-07-31",{"name":5,"class":6}]